Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
A consumer group is filing a lawsuit alleging that Aetna discriminates against patients with H.I.V. when it requires these patients to obtain medications exclusively throughout its own mail-order pharmacy, reports The New York Times.
Eighty-nine accountable care organizations will join the Centers for Medicare & Medicaid Services' Medicare Shared Savings Program starting in 2015, reports Modern Healthcare.
FDA-funded research by the Kaiser Permanente and Weill Cornell Medical College highlights the importance of registries and unique device identification implementation for post-market surveillance of medical devices.
The Office of the National Coordinator for Health IT has published a 53-page guide tailored specifically to implementing telehealth in critical access hospitals and rural areas.
The Argonaut Project has released its newly creater charter which seeks to accelerate nationwide health information sharing based on an internet-based open architecture and accelerate and focus HL7's development of FHIR interoperability standards and profiles.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
